SCHEMBL2064589

SCHEMBL2064589

COc1cc(C(F)(F)F)ccc1C(=O)NC1CCCn2c1nc(-c1ccncn1)cc2=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 11/20 0.39
BTK Q06187 2/20 0.38
TEC P42680 1/20 0.38
TXK P42681 1/20 0.38
BLK P51451 1/20 0.38
BMX P51813 1/20 0.38
ERBB4 Q15303 1/20 0.38
SLC6A9 P48067 2/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
CYP2D6 P10635 4/20 0.38
CYP1A2 P05177 3/20 0.38
PROKR1 Q8TCW9 1/20 0.37
KDR P35968 2/20 0.37
TEK Q02763 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064913 0.90 GSK3B (0.49) GSK3BHCRTR1HCRTR2CYP2D6CYP1A2
SCHEMBL3662679 0.88 GSK3B (0.44) GSK3BBTKSLC6A9CYP2D6CYP1A2
SCHEMBL2064592 0.88 F10 (0.44) GSK3BCYP2D6CYP1A2
SCHEMBL2066336 0.88 CRBN (0.46) GSK3BBTKTECTXKBMX
SCHEMBL2065317 0.87 GSK3B (0.48) GSK3BHCRTR1HCRTR2CYP2D6CYP1A2
SCHEMBL2065359 0.87 GSK3B (0.46) GSK3BHCRTR1HCRTR2CYP2D6CYP1A2
SCHEMBL2065354 0.86 GSK3B (0.41) GSK3BCYP2D6CYP1A2
SCHEMBL2065363 0.86 F10 (0.43) GSK3BCYP2D6CYP1A2
SCHEMBL2066117 0.86 CRBN (0.45) GSK3BBTKCYP2D6CYP1A2
SCHEMBL2065434 0.85 GSK3B (0.45) GSK3BHCRTR1HCRTR2CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148364-B2 Substituted bicyclic pyrimidone derivatives SANOFI-AVENTIS (FR) 2012-04-03 US claimed
EP-1957492-B1 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES SANOFI AVENTIS (FR) 2010-11-10 EP claimed
US-20090036427-A1 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-02-05 US claimed
EP-1790649-A1 Substituted bicyclic pyrimidone derivatives Sanofi-Aventis (FR) 2007-05-30 EP claimed
US-8148364-B2 Substituted bicyclic pyrimidone derivatives SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
EP-1957492-B1 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES SANOFI AVENTIS (FR) 2010-11-10 EP disclosed
US-20090036427-A1 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2009-02-05 US disclosed
EP-1957492-A2 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES sanofi-aventis (FR) 2008-08-20 EP disclosed
EP-1790649-A1 Substituted bicyclic pyrimidone derivatives Sanofi-Aventis (FR) 2007-05-30 EP disclosed
WO-2007057790-A2 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036427-A1 SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES GSK3B, GSK3A, PSEN1 GSK3B 1/4885BTK 599/4885TEC 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.